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Abstract
The characteristic neuropathological changes associated with Alzheimer’s disease (AD) and other lines of evidence support
the amyloid cascade hypothesis. Viewing amyloid deposits as the prime instigator of dementia has now led to clinical trials
of multiple strategies to remove or prevent their formation. We performed neuropathological and biochemical assessments
of 3 subjects treated with bapineuzumab infusions. Histological analyses were conducted to quantify amyloid plaque
densities, Braak stages and the extent of cerebral amyloid angiopathy (CAA). Amyloid-b (Ab) species in frontal and temporal
lobe samples were quantified by ELISA. Western blots of amyloid-b precursor protein (AbPP) and its C-terminal (CT)
fragments as well as tau species were performed. Bapineuzumab-treated (Bapi-AD) subjects were compared to non-
immunized age-matched subjects with AD (NI-AD) and non-demented control (NDC) cases. Our study revealed that Bapi-AD
subjects exhibited overall amyloid plaque densities similar to those of NI-AD cases. In addition, CAA was moderate to severe
in NI-AD and Bapi-AD patients. Although histologically-demonstrable leptomeningeal, cerebrovascular and neuropar-
enchymal-amyloid densities all appeared unaffected by treatment, Ab peptide profiles were significantly altered in Bapi-AD
subjects. There was a trend for reduction in total Ab42 levels as well as an increase in Ab40 which led to a corresponding
significant decrease in Ab42:Ab40 ratio in comparison to NI-AD subjects. There were no differences in the levels of AbPP,
CT99 and CT83 or tau species between Bapi-AD and NI-AD subjects. The remarkable alteration in Ab profiles reveals
a dynamic amyloid production in which removal and depositional processes were apparently perturbed by bapineuzumab
therapy. Despite the alteration in biochemical composition, all 3 immunized subjects exhibited continued cognitive decline.
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Introduction
The most common form of dementia is Alzheimer’s disease
(AD), currently affecting about 24 million people worldwide with
expected doubling of incidence every 20 years [1]. The disease is
neuropathologically characterized by the profuse deposition of
fibrillar amyloid-b (Ab) peptides, amyloid plaques (AP) and
cerebral amyloid angiopathy (CAA) as well as the intraneuronal
accumulation of neurofibrillary tangles (NFT) mainly composed of
tau protein. The abundance of these lesions has lent support to the
amyloid cascade hypothesis as the fundamental causative incident
in the pathogenesis of AD. This model has been reinforced by the
fact that AP, CAA and NFT are also present in familial AD (FAD)
due to presenilin (PS) and amyloid-b precursor protein (AbPP)
mutations and are recapitulated in genetically-engineered trans-
genic (Tg) mice bearing mutated forms of AbPP, PS and tau.
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Furthermore, individuals with Down’s syndrome carrying 3 copies
of chromosome 21, the location of the AbPP gene, also develop
the neuropathology of AD.
At present, there is no effective disease-modifying treatment for
AD. However, the abundant deposits of insoluble Ab and elevated
values of soluble oligomeric Ab have prompted the design of
multiple active and passive immunotherapies aimed at removing
the toxic forms of these peptides [2,3]. An example of one of the
passive immunization treatments is bapineuzumab, a humanized
monoclonal antibody (3D6) directed specifically against the N-
terminal region of Ab (residues 1–5) [4]. Although passive and
active immunotherapies have been effective in the removal of Ab
in AbPP and PS Tg mice models, the application of these
interventions to AD patients has been only partially successful
from a neuropathological perspective [5–9], while no clear
beneficial modification of the disease course has been observed
in clinical trials [7,10,11].
In this study we assess the clinical history, neuropathological
and biochemical outcomes in 3 individuals that participated in
clinical trials evaluating bapineuzumab [12] (ClinicalTrials.gov
Identifier NCT00112073) and who received 2, 6 or 20 immuno-
therapy doses. We quantified and characterized the levels of
soluble and insoluble Ab peptides that remained in the frontal and
temporal lobes of bapineuzumab-immunized AD (Bapi-AD)
patients and compared them to 4 age-matched non-immunized
AD (NI-AD) and 4 age-matched non-demented control (NDC)
individuals. AbPP and its C-terminal (CT) peptides as well as the
cytokine tumor necrosis factor-a (TNF-a) were also quantified. We
also compared the bapineuzumab observations with those
obtained from subjects who received AN-1792 immunotherapy.
Materials and Methods
Clinical and Neuropathological Reports and Treatment
Synopsis
The present report deals with the neuropathological and
biochemical observations made on 3 Bapi-AD patients and their
comparison to NI-AD and NDC individuals. Brain samples from
cases #1 and #2 were obtained from the Banner Sun Health
Research Institute (BSHRI) Brain and Body Donation Program
[13] whose operations have been approved by the Banner Health
Institutional Review Board. All subjects enrolled in the Brain and
Body Donation Program sign an informed consent approved by
the Banner Health Institutional Review Board. The brain tissue
for case #3 was provided by the Institute for Memory
Impairments and Neurological Disorders and the University of
California Alzheimer’s Disease Research Center (UCI-ADRC).
Participants enrolled in the UCI-ADRC provide informed consent
approved by the UCI Institutional Review Board. A summary of
subject demographics and neuropathology is presented in Table 1.
Case #1
For a detailed clinico-pathological description of case #1 the
reader is referred to our recent publication [14]. In brief, a 79-
year-old female was diagnosed with AD about 8 years prior to
death. The patient received 4 doses of bapineuzumab (each dose
0.5 mg/kg) over a period of 39 weeks in the extension portion of
the clinical trial. About 1 month after the last dose, the patient
showed symptoms and signs of vasogenic edema on an MRI scan
that was cleared prior to her death. There were no apparent signs
of disease modification that could be attributed to the immuno-
therapy treatment. Neuropathological analysis revealed frequent
AP and NFT and a concurrent diagnosis of both AD and
Binswanger’s type of vascular dementia. Case #1 was incorpo-
rated in the present biochemical evaluations of cases #2 and #3
to increase the sample size. Furthermore, in the previous analysis
of case #1, we only characterized the frontal region, while in this
communication we added the temporal region.
Case #2: Clinical History
An 89-year-old man died with a diagnosis of AD about 12 years
after symptom onset. The available private medical records
include his first presentation, about 11 years prior to death, when
he was seen by a neurologist for a several month history of
cognitive deterioration following biopsy for temporal arteritis. He
had been getting lost even when going for a walk close to home
and had been repeating himself frequently. Additionally, he was
being treated for depression. On examination he was not oriented
to place. He scored 23/30 on the Mini Mental State Examination
(MMSE), losing points on delayed recall and orientation. Gait and
posture were normal with no focal neurological signs. Brain MRI
showed only ectasia of the intracranial segment of the left vertebral
artery. An EEG was interpreted as within normal limits. He was
started on Aricept for a presumptive diagnosis of early Alzheimer’s
dementia, but this was quickly switched to Exelon because of
gastrointestinal side effects. Over the next 10 years, his cognitive
status declined only very slowly as documented by MMSE scores
of 20/30, 19/30 and a final score of 21/30 about 1 month prior to
death. Over this time period, he developed aggressive behavior
and was treated with an anti-psychotic agent. He developed startle
myoclonus, a stooped posture and a tremor. An EEG showed only
slowing and disorganization. About 1 year prior to death, he had
orthostatic hypotension with syncopal episodes and few months
prior to death was hospitalized for bradycardia. He received
annual standardized neurological and neuropsychological assess-
ments at BSHRI between 2003 and 2011. The diagnostic
impression was of dementia due to probable AD, with gait ataxia
and essential tremor. His past medical history is otherwise notable
for hyperlipidemia, mitral valve prolapse, first degree atrioven-
tricular block, chronic obstructive pulmonary disease, glucose
intolerance, thyroid nodules, bilateral cataract extractions, glau-
coma and benign prostatic hypertrophy. The family history is
notable for late-onset dementia in his mother.
Between January 2006 and January 2007, the patient was
enrolled in the bapineuzumab clinical trial AAB-201 (Clinical
Trials.Gov Identifier NCT00112073). In April 2007 the patient
began to participate in the bapineuzumab open label clinical trial
AAB-001, and was in this program until January 2011. During
these periods, this patient received 20 infusions of bapineuzumab
(each at 1 mg/kg) over a period of 260 weeks. Each infusion of
bapineuzumab was administered approximately every 3 months.
The apolipoprotein E (APOE) genotype of this individual was e2/
3.
Neuropsychological data were available for 2003, 2004, 2009,
and 2011. In the memory domain, Rey AVLT total learning
showed consistent decline from low average to mildly impaired.
He was unable to recall any AVLT information at delay in any
testing year. Recognition memory raw scores varied but were
within impaired ranges across years. Narrative recall (WMS-R
logical memory) was administered in 2009 and 2011 with only
mild to moderate impairment noted in both years. Visual memory
(BVMT-R) was administered in 2009 and 2011 only and
performance was moderately to severely impaired in both years.
Simple visual attention (TMTA) declined from low average to
moderately impaired over four testing epochs. Simple auditory
attention (Digits forward) improved from mildly impaired in 2003
and 2004 to low average in 2009 and 2011; this is a difference of
one point improvement in span. Executive functions (as measured
Outcomes of Bapineuzumab Immunotherapy
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by Stroop C/W and Trail Making Test B) declined over time from
low average to moderate to severe impairment. Confrontation
naming reduced from 26/30 correctly identified objects in 2009 to
21/30 in 2011. Judgment of Line Orientation (JLO) was in the
average range in the first 3 testing years. JLO was not
administered in 2011 due to inability to complete sample items.
The subject began to exhibit color discrimination problems in
2011. Consistent performance was noted on the MMSE (24, 21,
24, 21, respectively) and the clock drawing task (10/10 each year).
Verbal fluency was variable across epochs. Phonemic fluency was
average in 2003 and 2004, above average in 2009, and measured
in the low end of the average range in 2011. Semantic fluency for
animals was mildly impaired in 2003, low average in 2004,
average in 2009, and low average in 2011. Over the course of 8
years, this subject generally displayed a downward trend in
cognition with a few exceptions for specific tests.
Case #2: Neuropathology Report
Gross examination. The brain weight at autopsy was
1132 g. The dura was normal and the leptomeninges showed
moderate fibrosis. The convexities were symmetrical and showed
moderate gyral atrophy of the frontal lobes, moderate to severe
gyral atrophy of the parietal lobes and no gyral atrophy of the
occipital lobes. No focal lesions were present on the convexities or
base of the brain. The circle of Willis showed moderate patchy
atherosclerosis. The mammillary bodies were normal in shape,
color and size. The temporal lobes and unci showed mild to
moderate gyral atrophy. The cerebellum and brainstem were
externally normal. Cerebral slices showed moderate to marked
enlargement of the posterior horns of the lateral ventricles and
mild dilatation elsewhere. The basal ganglia, thalamus and
subthalamic nucleus were unremarkable. The amygdala showed
moderate atrophy in the left hemisphere and severe atrophy in the
right hemisphere with compensatory enlargement of the temporal
horns. The head of the hippocampus was mildly atrophied in both
hemispheres. The body of the hippocampus and the parahippo-
campal gyrus were both mildly atrophied. The substantia nigra
showed mild depigmentation bilaterally. Respective axial and
parasagittal slices of the brainstem and cerebellum were normal.
Microscopic examination. Paraffin sections of the left
hemibrain stained with hematoxylin and eosin (H&E) showed, in
sections of cerebral cortex, mild to moderate upper layer gliosis.
The amygdala and entorhinal cortex showed moderate to marked
gliosis. Area CA1 of the hippocampus showed mild gliosis. The
basal ganglia were unremarkable. There was mild to moderate
gliosis of the hypothalamus. Subthalamic regions including the
subthalamic nucleus and mammillary body were unremarkable.
The substantia nigra showed no apparent depletion of pigmented
neurons while the locus ceruleus was moderately to markedly
depleted; there were no Lewy bodies present in either region. The
cerebellar superior vermis showed moderate to marked patchy loss
of Purkinje cells. Remaining sections of the cerebellum, brainstem
and major levels of spinal cord were unremarkable. Large sections
stained with H&E showed no significant cerebral white matter
rarefaction and no infarcts. There were several mineralized blood
vessels in the globus pallidus. Sections stained with Gallyas,
Campbell-Switzer and Thioflavine-S methods showed, in neo-
cortical regions, frequent senile plaques of the diffuse type while
neuritic and cored plaques had a patchy distribution, ranging from
sparse to frequent in the frontal, parietal and occipital lobes, with
moderate to frequent densities in the temporal lobe. Neurofibril-
lary tangles were also patchily distributed, ranging from sparse to
moderate to focally frequent in neocortical areas. Tangles were
frequent in the amygdala, entorhinal cortex and hippocampal
CA1 region. Argyrophilic grains were present at frequent densities
in the amygdala, entorhinal cortex and area CA1 of the
hippocampus. There were frequent Gallyas-positive glial cells
around the circumference of the amygdala; these resembled small
astrocytes with spiky processes. Cerebral amyloid angiopathy was
present at sparse to moderate to focally frequent densities in most
cerebral cortex regions while there were focally moderate densities
in the cerebellar leptomeninges. Immunohistochemical staining for
phosphorylated a-synuclein showed no evidence of immunoreac-
tive inclusions or associated neurites in the olfactory bulb,
brainstem, amygdala or cerebral cortex. Diagnosis: Alzheimer’s
disease; argyrophilic grains and non-specific glial tauopathy,
mesial temporal lobe. Comment: This microscopic examination
confirms the clinical diagnosis of AD. Argyrophilic grains are
a microscopic finding of uncertain significance; they occur in
approximately 25% of cognitively normal older people as well as
a similar fraction of those with AD and other aging brain
disorders. They are often, as in this case, accompanied by a non-
specific glial tauopathy.
Case #3: Clinical History
This patient was an 86-year-old man with 12 years of education,
who presented with a 4-year history of memory impairment of
sudden onset prior to his initial evaluation in 1999 at the UCI-
ADRC. He was followed longitudinally by the ADRC Clinical
Core with slow progressive decline. The patient was screened for
participation in the bapineuzumab clinical trial in August of 2006,
and enrolled in this double blind randomized multicenter study
with a moderate level of cognitive impairment (MMSE 17/30).
This patient received only 2 doses of 2.0 mg/kg of bapineuzumab.
The first infusion was given in September of 2006, followed by the
second infusion 13 weeks later. MRI scans were completed for
safety assessment 6 weeks after each infusion and acute vasogenic
edema was observed on the safety scan at 6 weeks following the
second infusion. Progressive cognitive decline occurred with
a MMSE of 8/30 measured just 6 months prior to death. At
autopsy, sufficient neuropathology for a diagnosis of AD with
Lewy body disease was observed with a Braak stage VI. The APOE
genotype of this individual was e3/4.
Case #3: Neuropathology Report
Gross examination. The brain weight at autopsy was
1170 g. On external examination the cerebral gyri and sulci were
of normal gross appearance. The cerebral arteries and their major
branches at the base of the brain showed moderate focal
atherosclerosis, with up to 40% narrowing of the lumen. Coronal
sections of the right cerebrum showed the presence of mild gyral
narrowing and sulcal widening in the sylvian region. The lateral
Figure 1. Amyloid plaques and vascular amyloid in Bapi-AD and NI-AD. Amyloid plaques in frontal (A, C and E) and temporal (B, D and F)
lobes and vascular amyloid (G and H). A) and B) Campell-Switzer staining of Bapi-AD case #2 (89 year old male, APOE e2/3 genotype). C) and D)
Campbell-Switzer staining of NI-AD case #12 (87 year old male, APOE e2/3). E) and F) Thioflavine-S staining of Bapi-AD case #2. Frequent amyloid
plaques are shown in all cases. G) Leptomeninges of Bapi-AD case #2 stained with Thioflavine-S. H) Cortical blood vessels of Bapi-AD case #2
stained with Thioflavine-S. A–F were taken at 1006magnification and the scale bar is shown in caption A. G and H were taken at 25X with the scale
bars shown in each caption.
doi:10.1371/journal.pone.0059735.g001
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ventricle did not appear to be enlarged, although the hippocampus
was judged to be small. Horizontal sections of the brainstem and
cerebellum revealed normal intensity of neuromelanin pigmenta-
tion within the substantia nigra and markedly reduced intensity of
pigmentation within the locus ceruleus.
Microscopic examination. Blocks of tissue were examined
from middle frontal, superior temporal, inferior parietal, calcar-
ine/pericalcarine, and rostral and caudal cingulate cortex and
white matter, as well as from hippocampus, amygdala, corpus
striatum, thalamus, midbrain, pons, medulla, and cerebellum.
Both diffuse and neuritic (Braak and Braak stage C) plaque
formation were intense within frontal, temporal, parietal, occipital,
and rostral and caudal cingulate cortex and within hippocampal
CA1, subiculum, entorhinal-transentorhinal region, and amygda-
la. Within the cerebral neocortex neuritic plaques were more
prominent and densely stained (in both modified Bielschowsky and
Ab-stained sections) within the superficial layer than within deeper
layers while the number of plaques appeared to be similar, but
lighter in stain intensity. These findings were also observed within
the hippocampal formation, particularly within the subiculum
and, even more strikingly, within the amygdala, where the
intensity of Ab immunostaining within many of the neuritic
plaques was markedly reduced. Vascular intramural Ab deposition
was also observed in moderate degree within frontal and occipital
Figure 2. Amyloid plaques and vascular amyloid in Bapi-AD and NI-AD. Amyloid plaques in frontal (A, C, E) and temporal (B, D, F) lobes
and vascular amyloid (G and H). A) and B) Bielschowsky stain of Bapi-AD case #3 (86 year old male, APOE e3/4 genotype), showing a moderate
amyloid plaque accumulation. C) and D) Campbell-Switzer staining of NI-AD case #10 (91 year old female, APOE e3/4 genotype), exhibiting frequent
amyloid plaques. E) Thioflavine-S staining in the frontal cortex of case of Bapi-AD case #3 showing amyloid plaques and NFT in the background. F)
Double immunolabeling of amyloid plaques of Bapi-AD case #3 with antibodies against Ab40 (brown) and Ab42 (blue) demonstrating that the
amyloid plaques contained both peptide species. Cortical blood vessels of Bapi-AD case #3 (G) and Bapi-AD case #1 (H) stained with Thioflavine-S.
Magnifications: A, C, D, E, F –100X and B –40x.
doi:10.1371/journal.pone.0059735.g002
Figure 3. Representative images of immunohistochemistry showing microglia and T-lymphocytes. A) CD68 staining of the microglia in
the temporal cortex of NDC case #21. B) CD68 staining of the temporal cortex of NI-AD case #11. C) CD68 staining of the temporal cortex of Bapi-
AD case #2. D) HLA-DR staining of microglia in the frontal cortex of NDC case #21. E) HLA-DR staining of the temporal cortex of NI-AD case #11. F)
HLA-DR staining of the temporal cortex of Bapi-AD case #2. G) HLA-DR staining of the temporal cortex of Bapi-AD case #3. H) CD3 staining of T-
lymphocytes in the temporal cortex of Bapi-AD case #3. Magnifications: A–F –200X and G, H –100X.
doi:10.1371/journal.pone.0059735.g003
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leptomeningeal and intracortical vessels and, in very mild degree,
within amygdala capillaries. Iron deposition, as seen with the aid
of Perl’s iron stains, was minimal. Neurofibrillary degeneration,
which was judged overall Braak stage VI was severe at all sites
examined except for the calcarine cortex, where it was absent.
Granulovacuolar degeneration and Hirano body formation were
readily observed within hippocampal CA1. The concentration of
neuromelanin-bearing neurons was normal within substantia nigra
and moderately severely reduced within locus ceruleus. Alpha-
synuclein-immunoreactive intracytoplasmic Lewy inclusion bodies
were observed within substantia nigra, amygdala, subiculum,
entorhinal cortex and rostral cingulate cortex.
Neuropathological Evaluation
Bapi-AD cases #1 and #2, NI-AD and NDC subjects (BSHRI)
were evaluated for total plaque score, amyloid plaque density, total
CAA score, total NFT score, white matter rarefaction (WMR)
score, CERAD criteria, neuritic plaque score [15] and Braak stage
[16] as described in detail in previous publications [13,17,18]. As
part of the standard UCI-ADRC Neuropathology Core protocol,
blocks of fixed tissue from Bapi-AD case #3 were embedded in
paraffin and sectioned at 8 mm for a final standard neuropatho-
logical diagnosis (NIA Reagan criteria [19]). Modified
Bielschowsky, H&E, and Klűver-Barrera stains and immunostains
for tau, a-synuclein, ubiquitin, glial fibrillary acidic protein (GFAP
- astrocytes) and CD68 (microglia) were applied using standard
immunohistochemical protocols [20,21]. Braak staging was
assessed using silver-stained sections [16]. For additional experi-
mental studies, tissue blocks containing middle frontal gyrus and
hippocampus were sectioned with a vibratome at 50 mm intervals.
Standard immunohistochemical methods were used to detect Ab1–
40 and Ab1–42 (Biosource Internationial, Camarillo, CA) after
pretreatment with 90% formic acid for 4 min [22]. Thioflavine-S
(0.1%) staining was used to visualize whether existing plaques
containing Ab were fibrillar.
Assessment of Cerebrovascular Amyloid Angiopathy
(CAA)
To investigate the degree of vascular amyloidosis in the
leptomeninges, these membranes were carefully removed from
the convexities and medial aspect of the cerebral hemispheres,
prior to the brain coronal sectioning. The leptomeninges were
rinsed in phosphate buffered saline (PBS) and frozen at 280uC
until the moment of utilization. To remove entrapped intravas-
cular blood, the leptomeninges were rinsed 6 times each with 2 L
of cold PBS, and a final rinse with 2 L of deionized water (DW).
The gleaming membranes were spread on the surface of 3 plastic
Petri dishes (14 cm diameter) and allowed to dry and adhere to the
plastic surface by heating in an oven at 65uC. The membranes
were fixed with absolute ethanol for 1 h, rinsed with DW and
stained with 1% aqueous Thioflavine-S for 15 min followed by 4
rinses with 70% ethanol to remove unbound fluorochrome and
immediately observed in an epifluorescence microscope. For the
appraisal of cortical vascular amyloid, 0.5 cm3 of cerebral cortex
were suspended in 600 ml of 50 mM Tris-HCl pH 7.5 buffer
containing 5% SDS and 0.01% sodium azide with continuous
stirring for 72 h until all tissue was lysed except the tufts of
insoluble blood vessels. The blood vessels were rinsed with 4 L of
DW, to remove excess SDS, and processed and stained as
described above for the leptomeninges.
Immunohistochemistry
Coronal free-floating, formalin-fixed sections of 40 mm thickness
were taken using a sliding freezing microtome from Bapi-AD cases
#1 and #2, NI-AD and NDC subjects and were washed in PBS,
0.3% Triton X-100 (PBS-Tx) buffer to remove the cryoprotectant
storage medium. For diaminobenzidine (DAB) signal develop-
ment, the sections were blocked for 30 min in 1% H2O2, washed
with PBS-Tx and incubated for 16 h at room temperature in their
respective primary antibodies supplied by Abcam: anti-CD68
(ab955; 1:1000 dilution), anti-anti-HLA-DR (ab2018; 1:1000
dilution) and anti-CD3 (ab16669; 1:500 dilution). Sections were
then washed in PBS-Tx, incubated in the appropriate secondary
biotinylated antibody for 2 h, washed with PBS-Tx and incubated
in avidin-biotin peroxidase (ABC,Vector Labs) for 30 min. The
sections were placed in DAB for 3–8 min transferred to Tris-buffer
and mounted onto glass slides followed by a counterstain in 1%
neutral red and dehydration. The sections were coverslipped with
Permount mounting media (Fisher Scientific, Pittsburg, PA). For
fluorescence staining, the sections were reacted with rabbit anti-
GFAP (ab7260: Abcam, Cambridge, MA) at a 1:3000 dilution,
incubated at room temperature for 20 h on an orbital shaker and
then washed 6 times with PBS-Tx. The sections were incubated
with Alexa Fluor 488-conjugated goat anti-rabbit IgG for 2 h (A-
11034: Life Technology Corp. Carlsbad CA) at a 1:1000 dilution
followed by 6 washes in PBS-Tx and the sections mounted on glass
slides and dried. The slides were then sequentially submersed in
70% ethanol, 1% Sudan black in 70% ethanol, 50% ethanol,
rinsed with dH2O and mounted with Vectashield hard mount
media (Vector Labs, Burlingame CA).
Figure 4. Representative images of immunofluoresence staining of GFAP. A) Frontal cortex of NDC case #20. B) Temporal cortex of NI-AD
case #12. C) Temporal cortex of Bapi-AD case #1. For more details, see the Results section. Magnifications: A–C –200X.
doi:10.1371/journal.pone.0059735.g004
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Quantification of Soluble and Insoluble Ab by ELISA
A detailed description of ELISA methods has been previously
published [23]. In brief, gray matter from the frontal and temporal
lobes (100 mg) was gently homogenized in 800 ml of 20 mM Tris-
HCl, 5 mM EDTA, pH 7.8, protease inhibitor cocktail (PIC,
Roche Diagnostics, Mannheim, Germany), centrifuged at
435,0006g and the Tris-HCl-soluble supernatant collected. The
pellet was reconstituted in 600 ml of 90% glass-distilled formic acid
(GDFA), centrifuged at 435,0006g and the supernatant collected,
dialyzed against deionized water followed by 0.1 M ammonium
bicarbonate to remove the GDFA, then lyophilized. The
lyophilized material was reconstituted in 500 ml 5 M guanidine
hydrochloride (GHCl), 50 mM Tris-HCl, pH 8.0, PIC (Roche),
centrifuged and the supernatant collected. Total protein was
Figure 5. ELISA quantification of soluble and insoluble Ab in frontal and temporal lobes. A) Frontal cortex Tris-soluble Ab40. Notice the
sharp and significance difference between the Ab levels of NI-AD and those of the Bapi-AD. B) Temporal cortex Tris-soluble Ab40. There was a large
mean difference between NI-AD and Bapi-AD, however there was not a statistically significant difference due to the spread of values. Frontal (C) and
temporal (D) cortices GDFA/GHCl-soluble Ab40. In both cases there were significant elevations in mean Ab40 in Bapi-AD relative to NI-AD. Frontal (E)
and temporal (F) cortices Tris-soluble Ab42. In both lobes there were no statistical differences between the NI-AD and Bapi-AD due to the spread in
values. Frontal (G) and temporal (H) cortices GDFA/GHCl-soluble Ab42. There was a mean decrease in Bapi-AD Ab42 relative to NI-AD more noticeable
in the latter than in the former. The numbers in the Bapi-AD columns (1, 2 and 3), correspond to the cases #s given in Table 1. Statistical analysis
was performed using a one-way ANOVA followed by Tukey’s multiple comparison test (*p= 0.05–0.01; **p=0.01–0.001; ***p,0.0001). Abbreviations:
Tris, 20 mM Tris-HCl, 5 mM EDTA, pH 7.8, plus protease inhibitor cocktail; GDFA, glass-distilled formic acid; GHCl, 5 M guanidine hydrochloride,
50 mM Tris-HCl, pH 8.0, plus protease inhibitor cocktail; NDC, non-demented control; NI-AD, non-immunized Alzheimer’s disease; Bapi-AD,
bapineuzumab-immunized Alzheimer’s disease.
doi:10.1371/journal.pone.0059735.g005
Figure 6. Total levels (Ab40+Ab42) of soluble (Tris) and insoluble (GDFA/GHCl-soluble) Ab from the frontal and temporal lobes. A)
Frontal cortex total Tris-soluble Ab. B) Temporal cortex total Tris-soluble Ab. C) Frontal cortex total GDFA/GHCl-soluble Ab. D) Temporal cortex total
GDFA/GHCl-soluble Ab. For statistical treatment and abbreviations see legend to Figure 5.
doi:10.1371/journal.pone.0059735.g006
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determined for the Tris- and GDFA/GHCl-soluble extracts with
Pierce’s Micro BCA protein assay kit. Ab40 and Ab42 were
quantified with ELISA kits from Invitrogen (Carlsbad, CA)
according to manufacturer instructions.
Quantification of Tumor Necrosis Factor-a (TNF-a) by
ELISA
Gray matter (100 mg) was homogenized in 10 volumes of
20 mM HEPES, 1.5 mM EDTA, pH 7.4, PIC (Roche) as
previously communicated [23] and total protein concentrations
determined (BCA protein assay, Pierce). Human TNF-a levels
were quantified using an ELISA kit (PromoKine, Heidelberg,
Germany) following the manufacturer’s directions.
Western Blot Analysis
The complete materials and methods for Western blots have
been published elsewhere [23]. The antibodies applied for these
experiments were CT20AbPP (against the last 20 amino acids of
AbPP; #SIG-39152, Covance, Princeton, NJ) and tau (HT7 clone
against amino acids 159–163 of tau; #MN1000, Pierce, Rockford,
IL). For the secondary antibody, either HRP conjugated
AffiniPure goat-anti mouse IgG (#111-035-144, Jackson Immu-
noResearch, West Grove, PA) or HRP conjugated AffiniPure
goat-anti rabbit IgG, (#111-035-146, Jackson ImmunoResearch)
was used. In addition, a-mouse actin (#A65020, BD Transduction
Laboratories, San Jose, CA) or a-rabbit actin (#Ab37063, Abcam,
Cambridge, MA) was used as a total protein loading control.
Statistical Analyses
Statistical calculations were performed with GraphPad Prism 5
software (La Jolla, CA) using a one-way ANOVA followed by
Tukey’s multiple comparison test. Statistical significance was
determined by p values of #0.05.
Results
Table 1 shows a detailed account of the ages, gender,
postmortem intervals, brain weights, last MMSE scores, APOE
genotypes and neuropathological assessments of the NDC, NI-AD
and Bapi-AD cases employed in this study. In each of the NDC
and NI-AD groups there were 2 females and 2 males, while in the
Bapi-AD group there was 1 female (case #1) and 2 males (cases
#2 and #3). The mean ages of the individuals in these groups
were 80, 91, and 85 years, respectively. The average brain weight
of the Bapi-AD individuals was 1101 g which was very close to the
average weight of the NI-AD cases (1059 g), suggestive of some
degree of atrophy when compared to the mean weight of the NDC
group (1281 g). The Bapi-AD subjects had a final MMSE mean
value of 10 while the NI-AD and NDC MMSE values were 11 and
28, respectively. The APOE e4 allelic frequencies in the 3 groups
under study were: NDC = 13%, NI-AD = 38% and Bapi-
AD = 50%, respectively. The AP densities were zero to sparse in
the NDC cases while they were frequent in the NI-AD and Bapi-
AD cases (Table 1), as can be appreciated in Figure 1 and
Figure 2. Amyloid plaques were elevated between NDC and NI-
AD/Bapi-AD groups (Table 1). Neurofibrillary tangle Braak
stages were similar between NI-AD and Bapi-AD individuals
(Table 1). There was a wide variation in CAA content (Table 1):
none to mild in NDC, none to mild in NI-AD (with severe in the
occipital lobe of cases #12 and #13) and moderate to severe in
the case of the Bapi-AD (severe in the occipital and parietal lobes
of case #1). As shown in Table 1, there was a relatively wide
variation in total WMR score among the 3 groups.
As can be appreciated from Figure 1A, B, E, F and
Figure 2A, B, E, F, based on semi-quantitative visual analyses,
the Bapi-AD subjects harbored AP densities similar to those
observed in NI-AD cases (Figure 1C and D and Figure 2C
and D), which were matched for APOE genotype. No histological
evidence of extensive AP removal, patchy or otherwise, was
visually apparent in the 3 Bapi-AD subjects. Furthermore, the
density of CAA in the isolated vascular network of cerebral
Table 2. Ratio of Ab42:Ab40, as measured by ELISA, in the frontal in temporal lobes of NI-AD and Bapi-AD subjects.
FRONTAL TEMPORAL
NI-AD
Ratio Tris-soluble
Ab42:Ab40
Ratio GDFA/GHCl-
soluble Ab42:Ab40 NI-AD
Ratio Tris-soluble
Ab42:Ab40
Ratio GDFA/GHCl-soluble
Ab42:Ab40
10 2.73 131 10 3.14 185
11 1.84 66 11 1.83 87
12 2.19 93 12 1.65 101
13 3.28 137 13 2.15 75
Mean 2.51 107 Mean 2.19 112
Bapi-AD Ratio Tris-soluble
Ab42:Ab40
Ratio GDFA/GHCl-
soluble Ab42:Ab40
Bapi-AD Ratio Tris-soluble
Ab42:Ab40
Ratio GDFA/GHCl-soluble
Ab42:Ab40
1 0.154 2.00 1 0.67 5.36
2 0.163 5.11 2 0.35 6.39
3 0.608 7.93 3 0.04 4.78
Mean 0.308 5.01 Mean 0.35 5.51
*p= 0.0025 0.0037 0.0073 0.0153
Abbreviations: NI-AD, non-immunized Alzheimer’s disease; Bapi-AD, bapineuzumab-immunized Alzheimer’s disease; GDFA/GHCl, glass-distilled formic acid/5 M
guanidine-hydrochloride buffer.
*Unpaired 2-tailed, t-test.
doi:10.1371/journal.pone.0059735.t002
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cortices, stained by Thioflavine-S, demonstrated moderate to
severe deposition of amyloid in all 3 cases (Figures 1H, 2G and
2H). Whole-mount histological preparations of the entire
leptomeningeal vascular arbors of case #2, stained by Thio-
flavine-S, showed moderate to severe presence of vascular amyloid
distributed in a very homogeneous fashion (Figure 1G). Our
previously published report on Bapi-AD [14], which corresponds
to case #1 of the present study, showed severe leptomeningeal
CAA (see Figure 1D in reference [14]). Leptomeningeal Ab was
not assessed for case #3.
The Bapi-AD cases #1 and #2 exhibited a dense distribution of
microglia in the frontal and temporal cortices, as stained by the
CD68 antibody, relative to the NDC cases; however the microglial
density did not differ between Bapi-AD cases and NI-AD cases
(Figures 3A, B and C). This observation was confirmed by the
HLA-DR antibody (Figure 3D, E and F). HLA-DR immuno-
reactive activated microglia were seen in abundance within
cerebral cortex and white matter of Bapi-AD case #3, and were
even more numerous within subiculum and, particularly, within
the amygdala (Figure 3G). Cases #1 and #2 showed no T-cell
lymphocyte infiltration in either the frontal and temporal cortices.
In contrast, the Bapi-AD case #3 showed sparse but unequivocal
infiltration by CD3-immunoreactive T-lymphocytes, typically in
perivascular location, within cerebral cortex and white matter. T-
lymphocytes were observed in higher concentrations within
subiculum and, even more strikingly, within the amygdala
(Figure 3H). Immunofluorescence staining with GFAP demon-
strated fibrous astrocytes (Figure 4A). The NI-AD cases
(Figure 4B) appeared to have more voluminous astrocytic
cytoplasm and more frequent processes than the Bapi-AD group
(Figure 4C). Despite the higher levels of the proinflammatory
cytokine TNF-a in the temporal lobe of the Bapi-AD cases relative
to the NI-AD cohort, we did not observe commensurate changes
in the temporal lobe microglia morphology or density.
Quantification of Ab40 peptides by ELISA revealed that in the
frontal lobe and temporal lobe (Figures 5A and 5B) the Tris-
soluble fraction was, on the average, strongly increased in the
Bapi-AD cases relative to NI-AD by 18-fold and 32-fold,
respectively, although only the frontal lobe levels (Figure 5A)
reached statistical significance (p,0.05). In the temporal lobe, the
soluble Ab40 was not statistically significant due to the spread of
the values in the Bapi-AD (Figure 5B). In comparison, the NI-
AD group had only 2.0-fold (frontal lobe) and 2.7-fold (temporal
lobe) increases in amounts of Tris-soluble Ab40 as compared to the
NDC cohort (Figures 5A and 5B). A similar, but not as
dramatic, situation was observed for the Tris-extracted Ab42 pool
where the average levels were 2.3- fold and 1.4-fold increased in
the frontal and temporal lobes respectively, between the NI-AD
and Bapi-AD cases (Figure 5E and 5F).
Comparisons between Bapi-AD and NI-AD groups revealed an
apparently selective removal of GDFA/GHCl-solubilized fibrillar
Ab42, (Figure 5G and 5H), coupled with a concomitant increase
of insoluble fibrillar Ab40 (Figure 5C and 5D). In the frontal
lobe, the mean GDFA/GHCl-soluble Ab42 level in the Bapi-AD
group was 429 ng/mg total protein, while the mean level in the
NI-AD group as compared to 549 ng/mg total protein in the NI-
AD group, a 1.3-fold decrease in immunized cases (Figure 5G).
In contrast, the mean GDFA/GHCl-soluble Ab40 levels were
elevated 18-fold in the Bapi-AD group compared to the NI-AD
subjects (113 ng/mg and 6.2 ng/mg, respectively) (Figure 5C).
In the temporal lobe, a more dramatic apparent relative loss of
GDFA/GHCl-soluble Ab42 was evident, decreasing from 461 ng/
mg in the NI-AD cases to an average of 231 ng/mg in the Bapi-
AD cases, a 2-fold reduction (Figure 5H). Mean GDFA/GHCl-
soluble temporal Ab40 levels increased from 5.0 ng/mg in the NI-
AD group to a mean of 43 ng/mg in the Bapi-AD cases, an 8.6-
fold increase (Figure 5D).
Remarkably, Ab40 levels increased while Ab42 was decreased in
the Bapi-AD subjects relative to the NI-AD cohort, resulting in no
significant net change of GDFA/GHCl-soluble total Ab levels in
the Bapi-AD compared to NI-AD subjects (Figure 6C and 6D).
On the other hand, the levels of Tris-soluble total Ab were
significantly increased in the frontal cortex of the Bapi-AD cohort
compared to NI-AD (Figure 6A). Only Bapi-AD case #3 had
elevated Tris-soluble total Ab relative to the other 2 Bapi-AD
subjects in the temporal lobe (Figure 6B). This profound shift in
Ab40 accumulation in the Bapi-AD cohort was also evident in the
GDFA/GHCl-soluble fractions from the frontal and temporal
lobes in which Ab42:Ab40 ratios shifted dramatically after
immunotherapy.
Figure 7. ELISA quantification of tumor necrosis factor-a (TNF-
a). A) Frontal cortex TNF-a levels and B) Temporal cortex TNF-a levels.
Notice that there is a significant increase in the amount of this cytokine
in the temporal lobe of the Bapi-AD relative to NI-AD. For statistical
treatment and abbreviations see legend to Figure 5.
doi:10.1371/journal.pone.0059735.g007
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For the frontal and temporal lobes, the average Ab42:Ab40 ratios
in the GDFA/GHCl-soluble fraction were 107 and 112 in the NI-
AD group, respectively. These ratios were significantly decreased
to 5.0 and 5.5 in the Bapi-AD cases, respectively (Table 2).
Similarly, as shown in Table 2, the Tris-soluble average
Ab42:Ab40 ratios were significantly reduced in the immunized
cases relative to the NI-AD cases (Bapi-AD = 0.31 vs. NI-
AD = 2.51; 8.1-fold) in the frontal lobe, and in the temporal lobe
(Bapi-AD = 0.35 vs. NI-AD = 2.19; 6.3-fold).
In the frontal and temporal lobes the pro-inflammatory TNF-
a molecule was on the average increased in the Bapi-AD cases
relative to the NI-AD cases, but this difference reached a level of
statistical significance only in the temporal lobe (Figures 7A and
7B). As described above, removal of Ab in the Bapi-AD was more
extensive in the temporal lobe in comparison to the NI-AD group
which could explain the relative increase in this pro-inflammatory
cytokine.
Evaluation of the AbPP content by Western blot using the
CT20AbPP antibody revealed no statistically significant differ-
ences in the frontal and temporal lobes between the Bapi-AD and
NI-AD cases (Figures 8A and 8B). The CT20AbPP antibody
also detects the CT99 (,11 kDa) and CT83 (,9 kDa)
(Figures 8A and 8B), the peptides derived from the AbPP
proteolysis by the b- and a-secretases, respectively. These peptides
were significantly increased in the NI-AD frontal lobe when
compared to the NDC (Figure 8A), but showed no differences
from the Bapi-AD group. Identification of total tau by the HT7
antibody revealed the expected multiplicity of isoforms ranging
from ,58 to ,40 kDa. However, the overall quantities of these
isoforms did not show statistical differences among the studied
groups or brain regions (Figures 8C and 8D).
Discussion
Our investigation revealed: 1) On the basis of histology and
number, APs were apparently undisturbed in the Bapi-AD
individuals compared to age- and APOE genotype-matched NI-
AD cases; 2) Microgliosis and astrogliosis in the Bapi-AD and NI-
AD cases were increased relative to the NDC cohort while T-cell
lymphocyte infiltration was only present in Bapi-AD case #3; 3)
In the Bapi-AD subjects, the total amounts of Ab42 were reduced
relative to the Ab40 levels, which were concomitantly elevated; 4)
A remarkable reduction in the Ab42:Ab40 ratios between the Bapi-
AD and NI-AD cohorts; and 5) A lack of noticeable difference in
the relative levels of AbPP, CT99 and CT83 between Bapi-AD
and NI-AD despite the alterations in Ab42:Ab40 ratios. It is unclear
whether the shift in Ab peptide composition following immuno-
therapy represents a true compensatory physiological response to
AP and CAA disaggregation or simply reflects a new equilibrium
due to continuous AbPP processing under changed environmental
circumstances. Interestingly, in the Bapi-AD patients there was an
apparent increase in the Tris-soluble Ab pool relative to those
levels observed in the NI-AD cases. The pathophysiological
consequences of increased soluble Ab levels that are unable to exit
the brain are unknown.
A detailed examination of the individual responses to bapineu-
zumab in terms of the amount of antibody per infusion and
number of administered doses relative to Ab peptide levels did not
show a clear pattern for the Tris-soluble Ab fractions in both the
frontal and temporal lobes. However, in the Bapi-AD individuals
the levels of the GDFA/GHCl-soluble Ab40 and Ab42 fractions
had the tendency to cluster together.
Germane to the present study are our previous observations of
similar alterations in the Ab42:Ab40 ratio in the gray matter of the
frontal lobes of 7 patients actively immunized with the AN-1792
(containing the Ab42 peptide) vaccine which were compared to 6
NI-AD subjects [5]. ELISA of the GDFA/GHCl-extracted Ab
also revealed an average relative loss of Ab42 and a concomitant
average increase in Ab40 in the AN-1792 subjects. The average
Ab42:Ab40 ratios were 17.8 for the NI-AD and 0.59 for the AN-
1792 subjects, thus demonstrating trends analogous to those
exhibited in the current bapineuzumab study. As a group, the AN-
1792-immunized subjects demonstrated an average GDFA/
GHCl-soluble total Ab loss of 9.3%. Furthermore, the total Tris-
soluble Ab was 19-fold elevated in the AN-1792 subjects relative to
the NI-AD [5].
The ostensible preferential depletion in Ab42 by bapineuzumab
immunotherapy may reflect the antibody avidity for a specific
conformational domain of the Ab42 peptide. Molecular modeling
of Ab42 suggests an ionic bond between the N-terminal amino
group of 1Asp and the C-terminal carboxyl group of Ab42Ala [24]
at the surface of dimeric Ab42. This intramolecular conformation
may have a higher affinity for the antigen-antibody interaction.
Removal of dimeric Ab from the filamentous structures is in all
likelihood the way by which these structures are disassembled from
AP by antibodies, since the intermolecular bonds within dimers
are thermodynamically a billion times more stable than those
within free metastable monomers in a misfolded state [25–27].
Furthermore, bapineuzumab immunotherapy may be limited in its
effects because its specific epitope target is partially or totally
absent in a high proportion of deposited Ab peptides due to the
partial N-terminal degradation of these molecules [28,29] and to
the post-translational modifications such as Asp-isomerization [28]
and pyroglutamyl-cyclization [30], which enhance polymerization
and dimer resistance to enzymatic degradation [31]. In contrast,
the apparently more completely disaggregated ‘collapsed’ plaque
skeletons observed in AN-1792-immunized individuals [9] could
be a consequence of the polyclonal nature of this vaccine which
may have efficiently eliminated Ab42 as well as a wide range of
other species including N-terminally-degraded Ab peptides. If it is
true that a cascade of deleterious events leading to dementia
follows amyloid deposition, it suggests protective elimination of
both Ab40 and Ab42 must be preemptive and thorough.
It is important to bear in mind that although bapineuzumab
immunotherapy impacted Ab42 levels, it does not apparently
suppress the primary impetus for amyloidogenic AbPP processing
or deposition. The loss of Ab42 and the noticeable elevation of
Ab40 suggest a possible compensatory mechanism in which one
form of Ab is substituted for the other. For example, compensatory
deposition of Ab40 may explain the lack of remarkable differences
between AP densities in Bapi-AD and NI-AD individuals despite
Ab42 depletion. The apparent compensatory production and the
observed high levels of vascular amyloid in Ab-immunized
Figure 8. Western blot analyses of AbPP and its C-terminal peptides CT99, CT83 and of the tau isoforms. Frontal (A) and temporal (B)
cortices Western blots of CT20AbPP. The CT20AbPP antibody, raised against the last 20 amino acids of AbPP, was used to detect AbPP and its CT
peptides. Frontal (C) and temporal (D) cortices Western blots of tau. The tau isoforms were probed using the HT7 clone made against amino acids
159–163 of the tau molecule. Molecular weights, in kDa, are given on the left of each blot. Actin re-probes are shown below as a total protein loading
control. For comparison all Western blots were analyzed against NDC and NI-AD in the same gel. There were no statistical differences between the
immunized and non-immunized groups. Statistical analysis and abbreviations are described in the legend to Figure 5.
doi:10.1371/journal.pone.0059735.g008
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individuals lends support to the hypothesis postulating that one of
the functions of Ab peptides is to generate a protective hemostatic-
like patch/scab to seal leaky blood vessels at the abluminal side of
the brain microvessels (reviewed in [32–35]). Bapineuzumab
immunotherapy induces brain effusive vasogenic edema defined as
Amyloid Related Imaging Abnormalities (ARIA-E) and micro-
hemorrhages (ARIA-H) in AD individuals [36]. Flair-MRI scans
showed that 36 (17%) out of 210 bapineuzumab-treated AD
patients developed vasogenic edema and that 17 (47%) of these
patients developed microhemorrhages while only seven (4%)
patients out of the remaining 177 without ARIA-E developed
microhemorrhages [37]. Transient vasogenic edema has been
observed in other studies of Bapi-AD subjects [12,38,39]. A study
of 2762 AD patients at baseline in immunotherapy clinical trials
found AD-related vasogenic edema to be rare, occurring in only 2
cases [40]. The generation of microhemorrhages in immunized
AbPP Tg mice is a well documented observation [41–46]. It is
possible that blood-brain barrier (BBB) breaches could have been
caused by bapineuzumab or autoantibodies generated by the high
levels of Ab in addition to a vascular inflammatory reaction.
Taken together, these observations imply that partial removal of
Ab42 from the vascular walls by bapineuzumab immunotherapy
leads to a cycle of increased production of Ab40 in an attempt to
maintain the integrity of the BBB in the face of immunotherapy-
induced alterations.
Interestingly, in the Dominantly Inherited Alzheimer’s Network
(DIAN) study, 6% of young asymptomatic FAD mutation carriers
showed brain microhemorrhages, and 25% of mildly symptomatic
carriers also had these lesions of which 16% had 1–4 and 9% had
.5 microhemorrhages [47]. In addition, pure PS Tg mice,
without AbPP mutations and hence without AP, demonstrated
widespread ultrastructural microvascular pathology [48]. Older
AbPP/PS1 Tg mice (19–23 months of age), also developed
spontaneous ARIA-E and ARIA-H in areas adjacent to vascular
amyloid deposition in the absence of immunotherapy [49,50].
As the brain ages, inevitable microvascular decline and
accumulating damage decrease BBB integrity [51]. Chronic
diseases such as hypertension, hypotension, diabetes, atheroscle-
rosis, arteriosclerosis [52,53] as well as traumatic brain injury
[54,55] have a deleterious effect on brain microcirculation [56–
59]. Partial ligation of the thoracic aorta in pigs produces both
hypertension and a substantial increase in Ab40, Ab42 and p
412-tau
in the brains of these animals [60], suggesting general perfusion
failure synergizes the critical pathological cascades associated with
AD. The physical attributes of amyloid fibrils such as their
chemical stability, insolubility, amphipathic structure, cement-like
properties (reviewed in [32]), metal and heme binding capacity
[24,61–64] and their ability to interact with the extracellular
matrix to generate resilient meshes, similar to those of the
coagulation cascade, make amyloid an ideal brain microvascular
repair/protective substance [32,33,65]. Moreover, Ab binds and
sequesters plasma molecules that under normal circumstances
would be excluded from the brain [66–71]. The Ab peptides also
interact with key coagulation molecules including thrombin,
fibrinogen and plasminogen [72–78] and in this context the
AbPP770 and AbPP751 isoforms containing the Kunitz protease
inhibitor domain play an important regulatory role in the
coagulation cascade [79,80]. Moreover, in humans, the complex
amyloid deposits appear to be protected against proteolytic
degradation by a1-antichymotrypsin [81,82]. The continuous
and excessive accretion of amyloid around the brain microvessels
may terminate by constricting the lumen, creating blind capillary
stumps and impaired perfusion [32]. It can be postulated that the
brain of a patient with mild and moderate AD has attained or is
approaching an adaptive equilibrium in which amyloid production
has nearly reached a plateau [83]. Under these circumstances, the
removal of Ab42 may trigger a compensatory overproduction of
Ab40.
Anti-amyloid immunotherapy, in spite of a reduction of AP in
some areas of the brain [5–9,84] and/or dramatic alterations in
amyloid composition, has consistently failed to yield commensu-
rate changes in the clinical course of dementia [7,10,11]. Although
clinical trials of ponezumab, bapineuzumab and solanezumab for
mild and moderate AD were halted or did not achieve their
primary end points [11,85,86], other clinical trials using a variety
of immune approaches are still being evaluated. The observation
that anti-Ab immunotherapies produce substantial increases in
soluble Ab peptides provides a possible explanation for the weak
impact of these interventions against dementia. Soluble/oligomer-
ic Ab molecules have been isolated from AD brains [87] and these
peptides are clearly neurotoxic [88,89]. In addition, these species
have been largely incriminated as playing a central role in the
pathogenesis and pathophysiological evolution of AD and, to
a certain extent, displaced the insoluble plaque and vascular Ab as
the primary targets for therapeutic intervention. If these tenets are
correct, and in view of the present evidence, it would be expected
that in immunized AD patients, an increased pool of soluble
oligomeric Ab should aggravate the natural course of the disease.
Larger studies enabling more precise evaluation of the role played
by soluble/oligomeric Ab in immunotherapy recipients are
awaited.
The Alzheimer’s Prevention (Preclinical) Initiative (API) and the
DIAN studies will involve the proactive administration of anti-Ab
immunotherapy treatments to subjects harboring PS mutations
years prior to the estimated time of cognitive impairment
appearance. Clinical trials have confirmed that anti-amyloid
immunotherapy produces a range of considerable positive and
negative effects on critical biomarkers of sporadic AD [5–
9,12,14,39,84,90–95]. However, whether strategically timed pre-
symptomatic treatments will produce analogous responses and/or
preserve cognitive function in PS mutation carriers is uncertain.
Biochemical studies of PS mutations have led to the widely held
hypothesis that enriched production of Ab42 underlies dementia
[96,97], although rigorous quantitation of Ab peptides in humans
with FAD has revealed that this rule is clearly not universal
[98,99]. Whether or not crenezumab, solanezumab or gantener-
umab treatments favor Ab40 production and accumulation in
FAD-PS mutation carriers, API and DIAN will offer an ideal
opportunity to directly test the hypothesis that excess Ab42
production alone specifically initiates dementia emergence.
However, several lines of evidence, including the clinically
disappointing, but highly informative, outcomes of immunother-
apy trials suggest that dementia progression has an unappreciated
biochemical complexity. Our study and previous investigations of
the molecular aftermath of immunotherapy [5,9,14] suggest that
Ab40 may not be entirely benign, as elevated quantities of this
species are strongly associated with increased vascular amyloidosis
and continued decline into dementia. Again, the API and DIAN
will provide an ideal prospect to unequivocally examine the
potential association of these specific biomarkers with dementia
onset and progression as well as a test for the validity of the
amyloid cascade hypothesis.
In summary, our study and previous investigations confirm that
Ab immunotherapy profoundly impacts the prime AP and Ab42
targets. In some cases, immunotherapy resulted in the physical
disruption of AP. In the case of our study, although AP appeared
unaltered physically, the amyloid profile in treated subjects was
radically perturbed with levels of Ab42 substantially decreased and
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Ab40 levels increased. Despite these responses, immunotherapy did
not produce any substantial impact on dementia evolution. The
precise mechanism(s) underlying this equilibrium shift is unknown,
but the net effect of immunotherapy may be a marked preferential
accumulation of the shorter and more soluble Ab40 species.
Coupled with the recognized complexity of AD biochemistry and
neuropathology, these observations suggest that amyloid plaque
deposits either cannot be the sole instigator of cognitive
breakdown or their precise molecular constitution is of little
overall consequence to dementia appearance. If this is the case, it
suggests that despite remarkable impacts on AD biomarkers, the
consistent lack of success of immunotherapy against dementia
reflects the general failure to understand the function of amyloid
deposition and its dynamics comprehensively.
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